Scarab, NeoClone Sign License Agreement

Scarab Genomics has entered into a license agreement with NeoClone to market and distribute their antibodies against Shiga toxin. This toxin is secreted by E. coli bacteria, which is likely to cause disease or even death when consumed, most often in undercooked hamburgers.

Both the companies have indicated that the cost in developing the antibodies and the revenues will be shared.

Frederick Blattner, founder and president of Scarab Genomics, said: “We are confident the research and diagnostic markets will welcome access to these high quality reagents.”

NeoClone is a producer of monoclonal antibody products. It also provide large volume, contract monoclonal antibodies for companies and individual researchers.